Market Overview: Radiopharmaceuticals, which combine radioactive isotopes with pharmaceutical compounds, are increasingly utilized for both diagnostic and therapeutic purposes. The integration of ...

The global monoclonal antibodies market is poised for robust expansion, projected to surge from USD 208.32 billion in 2022 to USD 647.01 billion by 2032, reflecting a CAGR of 12% over the forecast ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

The “ Acute Myocardial Infarction Market Report ” by DelveInsight offers a robust analysis of market size, treatment ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

IntroductionGestational diabetes (GD) is a condition that occurs during pregnancy, where a woman without diabetes develops high blood sugar levels. The condition typically appears in the second or ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

This partnership, which officials said has the potential to be the largest ever U.S. industry-academic agreement of its kind, ...

May 9, 2025 /PRNewswire/ -- Eli Lilly and Company ... of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.

2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their long-standing alliance, with Lilly’s planned investment of up to $250 million ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) has announced a series of executive leadership transitions aimed at bolstering the company’s growth trajectory, particularly in the U.S. and ...